An observational study in Hypertension, Insulin Resistance Syndrome and Arterial Stiffness, sponsored by Hospital de Base. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Hospital de Base · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.
Among the 209 studies in Hypertension with a site in Brazil, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 8 that started in 2026, is one of 18 observational ones, reaches primary completion later than 22 of the 32 other live ones, and was the 205th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:
University of Nove de Julho · Sites in Brazil
Ages 18–65
AstraZeneca · Sites in Brazil
Ages 18+
Instituto Dante Pazzanese de Cardiologia · Sites in Brazil
Ages 18+
Raphael Mendes Ritti Dias · Sites in Brazil
Ages 60+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 40 · Phase 4 31
First in 1999; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 80 across the 189 interventional studies, 127 across the 18 observational. Of the 136 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 209 have an industry lead sponsor. The 10 most frequent:
Hospital de Base is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Hospital de Base has 5 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypertension with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07361276AstraZenecaObservational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System | 2026-11-30 |
| NCT06105775University of Sao PauloInorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies | 2026-12 |
| NCT06169241National Institute of Cardiology, Laranjeiras, BrazilEffect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients | 2026-12 |
| NCT06917131Universidade Federal FluminenseRoyal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension | 2026-12-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 209 studies in Hypertension with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease.
Arterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk.
At the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk.
Another important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack.
This study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods.
No additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.
Introduction
Hypertension remains a major global health problem and a leading contributor to cardiovascular morbidity and mortality. Large epidemiological studies have demonstrated a continuous and graded relationship between blood pressure levels and cardiovascular events, including myocardial infarction, stroke, and heart failure. However, traditional office blood pressure measurements do not fully capture the complexity of cardiovascular risk.
Arterial stiffness has emerged as a key marker of vascular aging and cardiovascular risk. Carotid-femoral pulse wave velocity (cf-PWV) is considered the gold standard non-invasive method for assessing aortic stiffness. Increased cf-PWV reflects cumulative vascular damage resulting from structural and functional alterations in the arterial wall, including elastin degradation, collagen deposition, vascular calcification, and endothelial dysfunction.
Insulin resistance is a central mechanism linking metabolic disorders to vascular dysfunction. It is associated with reduced nitric oxide bioavailability, increased sympathetic activity, chronic low-grade inflammation, and vascular remodeling. The triglyceride-glucose (TyG) index has been validated as a reliable surrogate marker of insulin resistance and has shown consistent associations with cardiometabolic outcomes.
Derived indices incorporating anthropometric parameters, such as TyG-WC, TyG-BMI, and TyG-WHtR, have been proposed to better capture the interaction between metabolic dysfunction and central adiposity. In addition, composite indices such as the body roundness index (BRI), metabolic score for insulin resistance (METS-IR), and cardiometabolic index (CMI) integrate multiple physiological domains and may provide incremental value in cardiovascular risk stratification.
Circadian blood pressure variation represents another important dimension of cardiovascular physiology. Blood pressure follows a daily rhythm, with a physiological increase in the early morning associated with sympathetic activation and hormonal changes. This phenomenon, known as the morning blood pressure surge (MBPS), has been associated with increased risk of cardiovascular events when exaggerated.
Arterial stiffness may amplify this morning increase in blood pressure due to reduced arterial compliance and impaired buffering of pulsatile flow. In addition, metabolic dysfunction may alter autonomic regulation and baroreflex sensitivity, further influencing circadian blood pressure patterns.
Despite strong biological plausibility, the integrated relationship between metabolic indices, arterial stiffness, and morning blood pressure parameters remains insufficiently explored. Understanding these interactions may improve early identification of individuals at increased cardiovascular risk.
Objectives
Primary Objective
To evaluate the association between arterial stiffness, measured by carotid-femoral pulse wave velocity, and the triglyceride-glucose (TyG) index.
Secondary Objectives
To assess associations between cf-PWV and TyG-derived indices (TyG-WC, TyG-BMI, TyG-WHtR); To evaluate associations between cf-PWV and composite metabolic indices (METS-IR, CMI, BRI); To investigate relationships between metabolic indices and morning blood pressure levels; To assess associations between metabolic indices and morning blood pressure surge (MBPS); To compare the performance of different metabolic indices in identifying increased arterial stiffness and morning hemodynamic load.
Methods Study Design and Data Sources
This is an observational, cross-sectional study with a prospective component, designed to evaluate the integrated relationship between metabolic indices, arterial stiffness, and circadian blood pressure patterns. The study adopts a hybrid design, combining data from two complementary sources: (1) previously collected data from an ethically approved research protocol and (2) prospectively collected data obtained under a standardized protocol.
Previously collected data will be used as secondary data, ensuring full anonymization and confidentiality. Prospectively recruited participants will provide written informed consent prior to inclusion. To ensure comparability, identical measurement protocols and definitions will be applied across both datasets.
Study Population
The study will include adults aged 18 to 65 years referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation in a specialized cardiovascular center. Participants will be included regardless of sex.
Only individuals not receiving antihypertensive treatment at the time of evaluation will be eligible for inclusion, in order to minimize the confounding effects of pharmacological therapy on arterial stiffness, metabolic indices, and circadian blood pressure patterns.
Participants will be classified according to 24-hour ABPM results into:
Normotensive individuals Untreated hypertensive individuals (defined as 24-hour mean blood pressure ≥130/80 mmHg) Clinical and Anthropometric Assessment
Baseline clinical data will include age, sex, and relevant medical history. Anthropometric measurements will be obtained using standardized procedures:
Body weight and height will be measured with participants wearing light clothing and no shoes; Body mass index (BMI) will be calculated as weight (kg) divided by height squared (m²); Waist circumference will be measured at the midpoint between the lowest rib and the iliac crest using a flexible tape measure.
In addition, the Body Roundness Index (BRI) will be calculated using a validated geometric formula incorporating waist circumference and height, providing an estimate of body fat distribution and central adiposity.
Office Blood Pressure Measurement
Office blood pressure (OBP) will be measured using a validated automated oscillometric device under standardized conditions. Measurements will be obtained after at least 5 minutes of seated rest, with the participant in a quiet environment.
Three consecutive readings will be recorded at short intervals, and the average of these measurements will be used for analysis. Heart rate will be recorded simultaneously.
Ambulatory Blood Pressure Monitoring (ABPM)
All participants will undergo 24-hour ABPM using a validated oscillometric device, applied to the non-dominant arm with an appropriately sized cuff.
The device will be programmed to obtain measurements:
Every 20 minutes during daytime (awake period) Every 30 minutes during nighttime (sleep period)
Daytime and nighttime periods will be defined based on individual sleep diaries. Only recordings meeting established quality criteria will be considered valid.
Mean systolic and diastolic blood pressure values will be calculated for:
24-hour period Daytime period Nighttime period
Hypertension will be defined based on a 24-hour mean blood pressure ≥130/80 mmHg.
Morning Blood Pressure and Morning Surge Definitions
Morning systolic and diastolic blood pressure will be defined as the average of readings obtained during the first two hours after awakening.
Morning blood pressure surge (MBPS) will be assessed using two complementary definitions:
Sleep-through MBPS (ST-MBPS): difference between morning systolic BP and the lowest nocturnal systolic BP value (including adjacent readings); Prewaking MBPS (PW-MBPS): difference between morning systolic BP and the average systolic BP during the two hours preceding awakening.
These indices will be analyzed as continuous variables and may also be evaluated across quartiles of metabolic indices.
Arterial Stiffness Assessment
Arterial stiffness will be assessed using carotid-femoral pulse wave velocity (cf-PWV), measured with a validated device under standardized conditions.
Participants will be evaluated in the supine position after at least 10 minutes of rest. Pulse waveforms will be recorded simultaneously at carotid and femoral sites.
At least three consecutive measurements will be obtained. For analysis, the mean of the two closest values will be used, provided that the difference between them is ≤0.5 m/s, ensuring measurement reproducibility and quality control.
Laboratory Data and Metabolic Indices
Laboratory data will be obtained from routine clinical tests performed under fasting conditions (minimum 8 hours), as requested by the treating physician.
The following parameters will be collected:
Fasting glucose Triglycerides HDL cholesterol
These values will be used to calculate metabolic indices:
Primary metabolic index TyG index: Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2] Derived indices TyG-WC = TyG × waist circumference TyG-BMI = TyG × BMI TyG-WHtR = TyG × waist-to-height ratio Composite indices METS-IR: Ln [(2 × glucose) + triglycerides] × BMI / Ln (HDL-C) CMI: (waist-to-height ratio) × (triglycerides / HDL-C) BRI: geometric index of body adiposity
All indices will be analyzed both as continuous variables and categorized into quartiles.
Study Variables Primary exposure: TyG index and derived metabolic indices Primary outcome: cf-PWV
Secondary outcomes:
Morning systolic and diastolic blood pressure ST-MBPS and PW-MBPS
Potential confounders will include:
Age Sex BMI 24-hour blood pressure Hypertension status Sample Size Considerations
The sample size was defined based on the primary association between cf-PWV and the TyG index, as well as the need to perform stratified analyses.
Given planned analyses involving quartiles of metabolic indices and stratification by hypertension status, a total sample size of approximately 800 participants was established to ensure adequate statistical power and stability of subgroup estimates.
Statistical Analysis
Continuous variables will be expressed as mean ± standard deviation or median (interquartile range), depending on distribution. Categorical variables will be presented as frequencies and percentages.
Participants will be categorized into quartiles according to metabolic indices. Comparisons across quartiles will be performed using analysis of variance (ANOVA) or appropriate non-parametric tests, with evaluation of linear trends.
Associations between metabolic indices and cf-PWV, as well as between metabolic indices and morning blood pressure parameters, will be assessed using linear regression models.
Multivariable models will be adjusted for predefined confounders based on biological plausibility. Interaction terms (e.g., metabolic indices × hypertension status) will be explored.
Additional analyses may include:
Concordance correlation coefficient (Lin's CCC) Bland-Altman analysis for bias assessment
A two-sided p-value \<0.05 will be considered statistically significant.
The study population will consist of adults aged 18 to 65 years referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation at a specialized cardiovascular center. Participants will include both normotensive individuals and untreated hypertensive individuals, classified based on 24-hour ABPM measurements. The study will include both previously collected data and prospectively recruited participants evaluated using standardized protocols.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with normal 24-hour blood pressure based on ABPM (\< 130/80 mmHg)
Adults with elevated 24-hour blood pressure (≥130/80 mmHg) not receiving antihypertensive treatment.
Carotid-femoral pulse wave velocity (cf-PWV)
Carotid-femoral pulse wave velocity (cf-PWV) will be measured as a marker of arterial stiffness using a validated non-invasive device under standardized conditions. The association between cf-PWV and the triglyceride-glucose (TyG) index will be evaluated.
Time frame: Baseline
Morning systolic blood pressure
Baseline
Time frame: Average systolic blood pressure during the first two hours after awakening, obtained from 24-hour ambulatory blood pressure monitoring (ABPM).
Morning diastolic blood pressure
Baseline
Time frame: Average diastolic blood pressure during the first two hours after awakening, obtained from ABPM.
Sleep-through morning blood pressure surge
Baseline
Time frame: Difference between morning systolic blood pressure and the lowest nocturnal systolic blood pressure value.
Prewaking morning blood pressure surge
Baseline
Time frame: Difference between morning systolic blood pressure and the average systolic blood pressure during the two hours preceding awakening.
Plan to share: No — Individual participant data (IPD) will be available upon reasonable request to the corresponding author, following publication of the study results. Data sharing will be subject to approval by the responsible ethics committee and compliance with applicable data protection regulations. De-identified data may be shared for research purposes only, under a data use agreement to ensure participant confidentiality.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Base